381 related articles for article (PubMed ID: 23915741)
21. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Johnston SR
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
[TBL] [Abstract][Full Text] [Related]
22. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
23. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
24. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
25. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
26. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
27. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
[TBL] [Abstract][Full Text] [Related]
29. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
30. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
31. Endocrine therapy: is the first generation of targeted drugs the last?
Pritchard KI
J Intern Med; 2013 Aug; 274(2):144-52. PubMed ID: 23844917
[TBL] [Abstract][Full Text] [Related]
32. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
33. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
35. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Provenzano A; Kurian S; Abraham J
Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
[TBL] [Abstract][Full Text] [Related]
36. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Dodwell D; Wardley A; Johnston S
Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
38. Endocrine therapy of advanced disease: analysis and implications of the existing data.
Pritchard KI
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
[TBL] [Abstract][Full Text] [Related]
39. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]